Grifols stock: Q3 cash flow advances debt reduction

Grifols reported stronger third-quarter operating results on November 2, 2026, as Biopharma growth, higher margins and improved cash generation supported further deleveraging. The company said full-year 2026 guidance remains unchanged. The figures and management commentary are contained in Grifols' SEC filing.

Biopharma Leads Quarterly Growth

Revenue reached EUR 2.04 billion in the third quarter, up 8.4% year over year at constant currency. Biopharma revenue increased 10.3% at constant currency, with immunoglobulin revenue rising 11.3%. Subcutaneous immunoglobulin revenue grew 40.3% in the quarter, while the Alpha-1 and Specialty Proteins franchise advanced 18.2%.

Albumin remained the main counterweight. Revenue in that business fell 13.2% at constant currency as regulatory conditions and elevated channel inventories weighed on sales in China. Grifols said it is expanding commercial channels in China and seeking additional geographic diversification.

Margins And Cash Flow Strengthen

Adjusted EBITDA rose 9.8% at constant currency to EUR 538 million, lifting the quarterly margin to 26.4%, 60 basis points above the prior-year quarter. Group profit increased 27.9% to EUR 162 million. Through September, revenue reached EUR 5.614 billion, adjusted EBITDA stood at EUR 1.392 billion and group profit rose 28.4% to EUR 390 million.

Free cash flow before mergers and acquisitions reached EUR 208 million in the quarter and EUR 298 million through September, EUR 110 million more than a year earlier. Net leverage declined to 3.98 times from 4.2 times in the prior-year period, while liquidity rose to EUR 2.14 billion. Grifols said refinancing of its 2027 obligations is complete and that it has no significant maturities until the fourth quarter of 2028.

Guidance And Research Milestones

Management continues to target a 25% adjusted EBITDA margin for the full year. The company also said its Egypt plasma network is on track to collect approximately one million liters in 2026, with the number of centers expected to increase from 18 to 20 by the first quarter of 2027.

Investors will also watch the Phase 3 SPARTA study of alpha-1 antitrypsin in emphysema. Grifols expects topline results by the end of the fourth quarter of 2026. The program and the China albumin market remain important tests for the durability of the company's growth and cash-generation strategy.

Grifols stock traded at 11.30 euros on Lang & Schwarz at 11:45 CET on Wednesday, November 11.

European investors are also tracking the IBEX 35 as Spanish equities absorb company-specific earnings signals and broader market moves.

See More news and analyses on Grifols stock.